Literature DB >> 16787239

Iron chelation as therapy for HIV and Mycobacterium tuberculosis co-infection under conditions of iron overload.

Debra Meyer1.   

Abstract

Iron chelators, as treatment for conditions of iron overload, have implications for AIDS and tuberculosis (TB) since excess iron in the system assists HIV and Mycobacterium tuberculosis (M.tb) multiplication. Excess iron, especially due to dietary habits, is almost as common in sub-Saharan Africa as infections by the two organisms. That HIV and M.tb influence each other's replication during co-infection is well established, but in vitro evaluations of concurrent infection of the two under conditions of iron overload and determining whether chelators reverse the effect, are limited. This review provides brief commentary on the possibility of iron chelators presently in clinical use influencing simultaneous HIV-M.tb infections during iron loading and the feasibility of evaluating this in vitro.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16787239     DOI: 10.2174/138161206777442164

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  11 in total

1.  Reactions of N-benzyloxycarbamate derivatives with stabilized carbon nucleophiles: a new synthetic approach to polyhydroxamic acids and other hydroxamate-containing mixed ligand systems.

Authors:  Yuan Liu; Hollie K Jacobs; Aravamudan S Gopalan
Journal:  J Org Chem       Date:  2009-01-16       Impact factor: 4.354

Review 2.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

Review 3.  Iron at the Centre of Candida albicans Interactions.

Authors:  Ruan Fourie; Oluwasegun O Kuloyo; Bonang M Mochochoko; Jacobus Albertyn; Carolina H Pohl
Journal:  Front Cell Infect Microbiol       Date:  2018-06-05       Impact factor: 5.293

4.  A major role for ferroptosis in Mycobacterium tuberculosis-induced cell death and tissue necrosis.

Authors:  Eduardo P Amaral; Diego L Costa; Sivaranjani Namasivayam; Nicolas Riteau; Olena Kamenyeva; Lara Mittereder; Katrin D Mayer-Barber; Bruno B Andrade; Alan Sher
Journal:  J Exp Med       Date:  2019-02-20       Impact factor: 14.307

5.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

Review 6.  Iron in intracellular infection: to provide or to deprive?

Authors:  Sandro Silva-Gomes; Sílvia Vale-Costa; Rui Appelberg; Maria S Gomes
Journal:  Front Cell Infect Microbiol       Date:  2013-12-09       Impact factor: 5.293

7.  Deferoxamine compensates for decreases in B cell counts and reduces mortality in enterovirus 71-infected mice.

Authors:  Yajun Yang; Jing Ma; Jinghui Xiu; Lin Bai; Feifei Guan; Li Zhang; Jiangning Liu; Lianfeng Zhang
Journal:  Mar Drugs       Date:  2014-07-07       Impact factor: 5.118

8.  Heparin inhibits intracellular Mycobacterium tuberculosis bacterial replication by reducing iron levels in human macrophages.

Authors:  Rodrigo Abreu; Lauren Essler; Allyson Loy; Frederick Quinn; Pramod Giri
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

Review 9.  Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.

Authors:  Rodrigo Abreu; Pramod Giri; Fred Quinn
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

10.  Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?

Authors:  Maria Dalamaga; Irene Karampela; Christos S Mantzoros
Journal:  Metabolism       Date:  2020-05-08       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.